Placebo-controlled, randomised clinical trial: high-dose resveratrol treatment for non-alcoholic fatty liver disease.

@article{Heebll2016PlacebocontrolledRC,
  title={Placebo-controlled, randomised clinical trial: high-dose resveratrol treatment for non-alcoholic fatty liver disease.},
  author={Sara Heeb\oll and Martin Kreuzfeldt and Stephen Jacques Hamilton-Dutoit and Marianne Kj{\ae}r Poulsen and Hans J St\odkilde-J\orgensen and Holger Jon M\oller and Niels Jessen and Kasper Thorsen and Ylva Kristina Hellberg and Steen B\onl\okke Pedersen and Henning Gr\onb{\ae}k},
  journal={Scandinavian journal of gastroenterology},
  year={2016},
  volume={51 4},
  pages={456-64}
}
OBJECTIVE "The obesity epidemic" has led to an increase in obesity-related conditions including non-alcoholic fatty liver disease (NAFLD), for which effective treatments are in demand. The polyphenol resveratrol prevents the development of experimental NAFLD through modulation of cellular pathways involved in calorie restriction. We aimed to test the hypothesis that resveratrol alleviates NAFLD in a randomised, clinical trial. MATERIALS AND METHODS A total of 28 overweight patients with… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 21 times over the past 90 days. VIEW TWEETS

Citations

Publications citing this paper.
Showing 1-10 of 18 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 31 references

Effect of resveratrol administration on metabolic syndrome, insulin sensitivity, and insulin secretion

  • M Mendez-del Villar, M Gonzalez-Ortiz, E Martinez-Abundis
  • Metab Syndr Relat Disord
  • 2014
1 Excerpt

Similar Papers

Loading similar papers…